FDA puts incentivization of device safety R&D, cybersecurity defenses on action plan

FDA
The FDA thinks manufacturers lack incentives to make new or existing devices safer unless they face an emerging safety concern. (FDA)

The FDA has established an action plan (PDF) for improving the safety of medical devices. Officials developed the strategy to address the emerging cybersecurity threat and to incentivize device designers to focus on safety innovations.

The 17-page document is split up into five sections that address the aforementioned topics plus the creation of a patient safety net, integration of pre and postmarket oversight and steps the FDA could take to intervene faster when safety threats arise. Collectively, the proposals are intended to ensure technological advances translate into safer devices, not just more efficacious products.

That thinking is at the heart of the FDA’s plans to incentivize the development of safer devices. As the FDA sees it, manufacturers currently lack incentives to make new or existing devices safer unless they face an emerging safety concern. The agency wants to use its powers to change that.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Commissioner Scott Gottlieb, M.D., and his device team are still figuring out exactly how the agency should intervene, but the action plan sketched out some possibilities. One option is to expand the kind of extra support the FDA provides through its breakthrough program to advances focused on safety, not efficacy. The FDA sees planned changes to the 510(k) program helping, too.

Another section of the document deals with pre and postmarket actions the FDA could take to boost cybersecurity. These include making manufacturers share details of their ability to patch security flaws in premarket submissions and creating a cybersecurity SWAT team to investigate breaches.

The FDA forsees the team, dubbed the CyberMed Safety (Expert) Analysis Board (CYMSAB), being a public-private partnership that acts as a resource for the agency and companies it regulates. CYMSAB would assess vulnerabilities and propose mitigating actions before problems arise, and carry out field investigations when the FDA or manufacturers suspects a device has been compromised. 

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.